Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a drug discovery and development partnerships with Celgene Corporation; Novo Nordisk A/S; Sanofi; Almirall, S.A.; Ferring Pharmaceuticals; Centogene AG; Immuneering Corporation; and LEO Pharma A/S. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Phone+49-40-560810
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2,178
OptionableNot Optionable
Evotec (ETR:EVT) Frequently Asked Questions
What is Evotec's stock symbol?
Evotec trades on the ETR under the ticker symbol "EVT."
What price target have analysts set for EVT?
3 Wall Street analysts have issued twelve-month target prices for Evotec's stock. Their forecasts range from €20.00 to €26.00. On average, they anticipate Evotec's share price to reach €22.67 in the next year. This suggests a possible upside of 15.4% from the stock's current price. View Analyst Price Targets for Evotec.
What is the consensus analysts' recommendation for Evotec?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec.
Has Evotec been receiving favorable news coverage?
Media stories about EVT stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evotec earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Evotec's key competitors?
Some companies that are related to Evotec include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Cannpal Animal Therapeutics (CP1), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF) and Cipher Pharmaceuticals (CPH).
Who are Evotec's key executives?
Evotec's management team includes the folowing people:
- Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
- Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
- Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
- Dr. Craig Johnstone, COO & Member of Management Board
- Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
What is Evotec's stock price today?
One share of EVT stock can currently be purchased for approximately €19.65.
What is Evotec's official website?
How can I contact Evotec?
Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.
MarketBeat Community Rating for Evotec (ETR EVT)
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
